Introduction
The development of resistance to classical agents in the treatment of typhoid fever has recently become a matter of great concern, with reports of cases of multidrug resistant strains not responding to ampicillin, chloramphenicol or trimethoprim from many parts of the world (Sharma el al., 1979; Antani, Kala & Kawat, 1988; Anand et al., 1990; Gupta, Bhujwala & Shriniwas, 1990; Khadilkar et al., 1990; Farid, 1992) . A dramatic rise in the number of multi-resistant Salmonella typhi strains recently in India is caused by the introduction of plasmid-mediated drug resistance into S. typhi conferring resistance to these three drugs of choice (Goldstein, Chumpitaz & Guevara, 1986; Schwalbe et al., 1990; Jesudason & John, 1992) .
The increasing frequency of multi-resistant S. typhi prompted revision of the treatment of typhoid fever and from 1991, the use of ciprofloxacin was recommended in some parts of the world including the UK, especially for travellers returning from areas where typhoid fever resistant to ampicillin, chloramphenicol and/or trimethoprim was common (Rowe, Ward & Threlfall, 1991) . The move to first-line ciprofloxacin therapy was accelerated by a sharp increase in the isolation of multi-resistant 5. typhi from patients who had recently returned from the Indian sub-continent to the UK (Rowe, Ward & Threlfall, 1990 .
The 4-quinolone drugs affect the functioning of prokaryotic DNA gyrase (Reece & Maxwell, 1991) , an essential type II DNA topoisomerase, responsible for introducing negative supercoils into covalently closed DNA with the utilisation of ATP. The action of the 4-quinolone drugs on the DNA gyrase enzyme is to destroy the enzyme's ability to catalyse DNA breakage and reunion, leading to an inhibition of processes such as DNA replication, recombination, decatenation and transcriptional regulation.
Some members of the Enterobacteriacae such as Escherichia coli and Salmonella typhimurium have been found to be less prone to the development of resistance to 4-quinolones than to older antibiotics. This probably results from a lack of plasmid carriage of 4-quinolone resistance. Quinolone resistance commonly arises as a result of cell membrane mutations leading to either a decrease in membrane permeability or an increased efflux of quinolones. Another possible mechanism for 4-quinolone resistance is the occurrence of chromosomal mutations in either or both gyrA and gyrB, the genes encoding the two sub-units of the DNA gyrase protein GyrA and GyrB (Wiedemann & Heisig, 1994) . This latter class of mutations results in a decreased affinity of DNA gyrase for these antibiotics.
Recent reports have shown that some S. typhi isolates do not respond to ciprofloxacin therapy (Bhatia, 1992; Rowe et al., 1992; Umasankar, Wall & Berger, 1992) . One of the isolations, in the UK, involved a patient whose preliminary blood culture showed sensitivity to ciprofloxacin, ampicillin, amoxycillin, co-trimoxazole and gentamicin; however resistance to ciprofloxacin occurred (with a ciprofloxacin MIC of 0.5 mg/L) by exposure to a sub-therapeutic dose of the drug, possibly for a sub-therapeutic period (Umasankar et al., 1992) . Another isolation from a patient recently returned from India, yielded ciprofloxacin-resistant S. typhi (MIC 0.3 mg/L) also resistant to ampicillin, chloramphenicol, streptomycin, sulphonamides, tetracycline and trimethoprim (Rowe et al., 1992) .
This report details the molecular alterations in DNA gyrase responsible for 4-quinolone resistance in isolates of 5. typhi isolated in Vellore, India.
Materials and methods

Bacterial techniques and MIC determination
Nutrient broth (Oxoid, Basingstoke, UK) was used for liquid culture growth and solidified with 1.5% agar in plates. Fresh solutions of each drug were prepared immediately before use and added aseptically to the growth medium. Minimum inhibitory concentrations (MIC) were determined by the micro-broth dilution method on solid media as described before (Lewin, Nandivada & Amyes, 1991) .
Preparation of chromosomal DNA
Chromosomal DNA was prepared by a slight modification of the protocol of Zyskind and Bernstein (1992) . A single colony was inoculated into 5 mL of nutrient broth and grown overnight in a 37°C incubator. A 1.2 mL volume of this culture was spun in a microcentrifuge (Microcentaur, MSE) for a period of 15 sec. The broth was discarded and the cell pellet resuspended in a volume of 0.31 mL HTE buffer (50 mM Tris.Cl, pH 8.0, 20 mM EDTA) by briefly vortexing, to which 0.35 mL of a 2% solution of sarcosyl in HTE was added with brief inversion of the tube, followed by 5 /JL RNase (10 mg/mL in TE buffer). A volume of 35 pL of pronase (10 mg/mL in 10 mM Tris.Cl pH 8.0, lOmM NaCl, 0.1 mM EDTA buffer) was added and the tubes incubated in a 50°C waterbath until lysis had occurred. Three rounds of phenol/chloroform extraction were carried out and the resulting lysate treated with a 10% volume of 3 M sodium acetate pH 5 and a 100% volume of isopropanol at -20°C. DNA precipitation was achieved after placing the tubes at -70 c C for 15 min followed by centrifugation at 13,000 rpm in a microcentrifuge for 20 min. The resulting pellet was briefly washed by the addition of 70% ethanol and then dried in a vacuum dessicator. Resuspension of the pellet in 100/iL of TE gave a solution of DNA suitable for amplification by the Polymerase Chain Reaction.
Amplification of a section of gyrA by the polymerase chain reaction
A 620 base pair region of gyrA was amplified from chromosomal DNA by use of a Taq polymerase kit obtained from Gibco BRL. The final volume in the tubes for amplification was 100 //L and consisted of 10 x Taq PCR buffer, 2.5 mM MgCb, 200 /ZM dNTPs, lOpmoles of each primer (5'ATGAGCGACCTTGCGAGAGAAATTAC-ACCG3' and 5TTCCATCAGCCCTTCAATGCTGATGTCTTC3' purchased from Oswel DNA Service, Department of Chemistry, University of Edinburgh), 0.1 fig DNA and 2 units of Taq polymerase. Primers were designed on inspection of the gyrA sequence of E. coli (Yoshida et ah, 1988) and correspond to nucleotide positions 1 to 30 and 590 to 620 of this sequence with the 3' primer being biotinylated. A Techne thermocycler was used for DNA amplification; the program chosen included a preliminary stage of 96°C for 30 sec, 50°C for 60 sec, 70°C for 90 sec followed by 24 cycles at 96°C for 15 sec, 50°C for 30 sec and 70°C for 90 sec. A final extension step ran at 70°C for 5 min. After confirmation of the correct PCR product being achieved by gel electrophoresis on a 1% agarose gel, the PCR product was either subjected to a sequencing reaction or to restriction endonuclease digestion.
DNA Sequencing
Sequencing was carried out directly from the PCR fragment with Dynabeads M-280 (Dynal A.S., N-0212, Oslo, Norway) to separate the strands. Sequencing was performed on single-stranded templates by the dideoxynucleotide chain-termination method (Sanger, Nicklen & Coulson, 1977) with p 5 S]-dATP (1200 Ci mmol"'; Amersham) and with a Sequenase version 2.0 kit (US Biochemicals) with both the 5' and 3' primers so that the fragment could be sequenced in both directions. Sequence gels were exposed to Kodak Biomax MR-1 film at room temperature for 48 h.
Hinf/ restriction fragment length polymorphisms
The enzyme Hinfl was purchased from Gibco BRL. A volume of 40 /iL of the gyrA PCR product was digested with Hinfl at 37°C for 2 h by the addition of REACT2 buffer (Gibco BRL) and 10 units of enzyme. The restriction fragments were run out on a 4% Metaphor gel (FMC Bioproducts, Rockland, ME) containing ethidium bromide and visualised under UV light.
Results
Levels of resistance to 4-quinolone drugs
Fifteen S. typhi isolates isolated in the Christian Medical Centre, Vellore, India were examined and compared throughout with sensitive Salmonella species control isolates. The MICs of ciprofloxacin, ofloxacin and nalidixic acid were determined as shown in the Table. Twelve out of 15 of the Indian isolates were found to have MICs of ciprofloxacin of 0.256 mg/L, a level considerably higher than expected. The three S. typhi isolates which were relatively sensitive to ciprofloxacin were also sensitive to ofloxacin and nalidixic acid. Similarly, the isolates showing decreased susceptibilities to ciprofloxacin had high levels of resistance to these two other drugs. It is interesting that the three S. typhi isolates remaining sensitive to ciprofloxacin were isolated from patients in either 1992 or 1993 whereas II of the 12 isolates which were markedly more resistant to this drug were isolated in 1994. Only one of the isolates (ST5), which was isolated in 1992 had a decreased susceptibility to 4-quinolone drugs and after investigating this, it can be speculated that the acquisition of quinolone resistance resulted from a different type of mutation compared to the other resistant isolates (see later). Since this initial survey showed that the isolates had high levels of resistance to the 4-quinolone drugs, a fuller survey was carried out to determine the MICs of the isolates to ampicillin, trimethoprim, chloramphenicol, streptomycin, sulphamethoxazole, tetracycline, gentamicin, amoxycillin/clavulanic acid, cefuroxime, 
Molecular analysis of the acquisition of ciprofloxacin resistance
A 620 bp fragment was amplified from the gyrA gene of each of the S. typhi isolates and the double-stranded DNA separated into single strands by the use of Dynabeads. After sequencing in each direction, a 486 bp region of the fragment, spanning the "Quinolone Resistance Determining Region" (QRDR) (Yoshida et al., 1990) , was read. The nucleotide sequences of the three ciprofloxacin-sensitive S. typhi isolates (ST3, ST7 and ST12) and ciprofloxacin-sensitive S. typhimurium were found to be identical (J. C. Brown, C. J. Thomson & S. G. B Amyes, 1996) . A ciprofloxacin-sensitive isolate of Salmonella arizoniae was also used as a sensitive control strain for sequence comparisons. The nucleotide sequence of ciprofloxacin-sensitive S. typhi along with the predicted amino acid sequence is shown in Figure 1 . Deviations from the amino acid sequence of both ciprofloxacin-sensitive S. typhi and 5. typhimurium were found in eleven of the 12 isolates with decreased susceptibilities to ciprofloxacin. In isolates ST1, ST2, ST4, ST8, ST9, ST11, ST13, ST14, ST15 a substitution of serine at position 83 to phenylalanine was found to have occurred. A change in both the secondary and tertiary structures of the enzyme could potentially occur as a result of a neutral polar amino acid change to a neutral non-polar amino acid with a side-group of a different shape. Isolates ST6 and ST10 were found to carry different mutations, namely a double mutation of serine-83 to phenylalanine and aspartate-87 to tyrosine in ST6 while ST10 showed a single mutation of aspartate-87 to tyrosine. This reported change of Ser-83 to phenylalanine is a novel amino acid substitution in gyrase-mediated ciprofloxacin resistance. The same change has been found to occur in ciprofloxacin-resistant 5. typhimurium (Brown et al., 1996) . It seems that E. coli and Salmonella could be predisposed to different amino acid changes at Ser-83 as a result of differential codon usage.
It has been postulated that this region of the protein is involved in the action of quinolone drugs with its close contact to the site of DNA attachment at tyrosine-122. All of the changes above could possibly make this site of DNA breakage and reunion less accessible. Clinical resistance to the 4-quinolone drugs resulting from a mutated GyrA protein seems to almost universally arise from a mutation in this stretch of the enzyme known as the Quinolone Resistance Determining Region (QRDR) (Yoshida et al., 1990) . However a different type of quinolone-resistance mutation was concluded to be the cause of the high quinolone MICs in isolate ST5. On sequencing the QRDR of this isolate, no amino acid substitutions were found. Quinolone-resistance in ST5 is thus likely to be attributed to either an outer membrane protein mutation or a mutation affecting efflux or perhaps a mutation in gyrB. It is interesting that ST5 was isolated in 1992 whereas all the other quinolone-resistant isolates with mutations in gyrA were isolated two years later in 1994.
Restriction fragment length polymorphisms in the gyrA PCR fragment
As a result of certain common gyrA mutations, for example some found in E. coli, often causing the abolition of a Hinfl restriction site in gyrA occurring within a region of the enzyme centred around Ser-83, Hinfl restriction was used as a screen for amino acid The DNA and predicted amino acid sequence of ciprofloxacin-sensitive 5. typhi gyrA (nucleotides 72 and 557, amino acids 24 to 185). The nucleotide sequence of the sense strand of the gyrA gene is presented from the 5' (left) and 3' (right) end. The deduced amino and sequence is given below the DNA sequence Amino acid positions are numbered, starting at codon 24. Deviations from the nucleotide sequence of E. coli (Yoshida et a!., 1988) are highlighted in bold.
substitutions in the QRDR (Fisher et al., 1989) . The sequence recognised and cleaved by this enzyme is G/ANTC, thus a gyrA PCR fragment of S. typhi amplified from an isolate with no amino acid substitution at serine-83 (nucleotide sequence encoding amino acids 82 and 83 being GATTCC) would be cleaved by the enzyme whereas a gyrA PCR fragment amplified from a quinolone-resistant isolate with a mutation at serine-83 (replaced by, for example, phenylalanine) would not be cut since this would change the nucleotide sequence at this area to GATTTC. In S. typhi, the DNA sequence encoding these two amino acids is GATTCC. As can be seen in Figure 2 , the gyrA PCR fragments amplified from isolates ST3, ST5, ST7, ST10, ST12, ST16 show a different restriction pattern from all the other isolates since there is no point mutation at serine 83 which leaves the Hinfl site. The enzyme Hinfl cuts the amplified 620 bp fragment of the wild-type S. typhi gyrA three times as shown in Figure 2 . This results in the digestion of the fragment into four sections of lengths 246 bp, 99 bp, 149 bp and 126 bp. Since the PCR fragments from ST1, ST2, ST4, ST6, ST8, ST9, ST11, ST13, ST14, ST15 do have a mutation at serine 83, thus abolishing the Hinfl site, the PCR product is only cut into three fragments of lengths 345 bp, 149 bp and 126 bp.
Discussion
The ciprofloxacin-resistant isolates tested show the occurrence of different mutations in the QRDR. These mutations are typical of the acquisition of ciprofloxacin resistance (Reece & Maxwell, 1991) . Like E. coli (Yoshida et al., 1988) and S. typhimurium for example (Brown et al., 1996) , the substitution of serine-83 and/or aspartate-87 in the QRDR of S. typhi has been found to be the likely mutation(s) leading to a decreased susceptibility to ciprofloxacin.
Mutations, including those reported here, which have been located in the gyrA gene, seem to be present only in a limited region of the enzyme, around tyrosine-122. Evidence suggests that drugs bind to DNA (Shen et al., 1989) and a model proposed is that quinolone drugs hydrogen-bond to a single-stranded DNA pocket formed after DNA cleavage by gyrase. The likely interaction of the gyrase-DNA complex with quinolones has also been studied by binding studies (Willmott & Maxwell, 1993) . Mutations occurring in this region, the QRDR, are in close contact to tyrosine-122 and probably affect the structure of a putative quinolone-gyrase-DNA complex. Recent evidence suggests that this DNA gyrase-quinolone-DNA complex prevents E. coli RNA polymerase transcription (Willmott et al., 1994) . In the absence of quinolones, the RNA polymerase can pass and even overtake DNA gyrase on the chromosome during transcription. However, when gyrase is associated with quinolone drugs, this covalently bonded DNA-protein complex causes the RNA polymerase to dissociate from the chromosome, resulting in prematurely terminated transcripts. A mutation at serine-83 of the GyrA protein conferring decreased susceptibility to ciprofloxacin has been found to change the structure of the protein in such a way that transcription by RNA polymerase is no longer blocked (Willmott et al., 1994) . Other classes of antibacterial agents such as novobiocin do not have this effect on transcription, thus this drug, which binds to the N-terminal domain of the GyrB sub-unit, rather than GyrA, has a different mode of inhibition on the DNA gyrase enzyme.
The work carried out suggests that there may soon be an increase in the number of patients not responding to 4-quinolone therapy in countries such as India. Recently, it has been recommended that ciprofloxacin should be adopted as the first-line treatment drug for S. typhi isolates isolated in the UK since it is likely that travellers returning from the Indian subcontinent may be harbouring multi-resistant isolates (Rowe et al., 1991) . Clearly in the near future, there may be instances where therapy with this drug of choice fails. It is significant that of the 12 quinolone-resistant isolates examined in this study, only ST10 did not respond to ciprofloxacin therapy when this drug was administered to a patient. The 11 other isolates examined had the same MIC for ciprofloxacin (0.256 mg/L), thus there is a possibility that these isolates could also become more resistant to quinolone drugs actually during the course of therapy, if, for example, a sub-therapeutic dose of the drug was given.
There is obviously a compelling need to review the status of chemotherapeutic options against multi-resistant isolates of S. typhi. In this in-vitro study, most of the isolates were insensitive to the commonly used antibiotics. The only drugs tested which were active were amoxycillin/clavulanic acid, gentamicin, cefuroxime, cefotaxime, ceftazidime and ceftriaxone. Indiscriminate use of antibiotics must be avoided to nprevent the emergence of further resistance. An alarming rise in multi-resistant isolates of S. typhi which are also 4-quinolone resistant may soon occur, necessitating the use of the more expensive third generation cephalosporins. This would pose a problem to health services in developing countries where such drugs may not be available.
